Company profile: TissueGene
1.1 - Company Overview
Company description
- Provider of regenerative biopharmaceutical therapies for orthopedic disorders, offering TG-C, an allogeneic cell and gene therapy designed to treat knee osteoarthritis by reducing pain, improving function, and slowing disease progression.
Products and services
- Orthopedic Disorders Therapy Focus: Focused on developing regenerative therapies for the treatment of various orthopedic disorders as a biopharmaceutical enterprise
- Regenerative
- Regenerative Orthopedic Therapies Development: Develops regenerative therapies for the treatment of various orthopedic disorders, creating orthopedic biopharmaceutical products
- Orthopedic-focused
- TG-C: An allogeneic cell and gene therapy engineered for knee osteoarthritis, reducing pain, improving function, and slowing disease progression in patients
- Allogeneic
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TissueGene
10x Genomics
HQ: United States
Website
- Description: Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 10x Genomics company profile →
CosmosID
HQ: United States
Website
- Description: Provider of metagenomics and bioinformatics services for rapid identification of microorganisms in various samples, offering strain-level analysis via proprietary pipeline and database to detect bacteria, viruses, fungi, and more. Provides sequencing services (amplicon, shallow/deep shotgun, bacterial isolate) and CosmosID-HUB Microbiome, an online platform with pipelines for amplicon and shotgun data, plus targeted tests and whole genome analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CosmosID company profile →
Vanadis Diagnostics
HQ: Sweden
Website
- Description: Provider of a novel non-invasive prenatal testing (NIPT) solution in development based on digital analysis of cell-free DNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanadis Diagnostics company profile →
Bamboo Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy development, research, and manufacturing for rare genetic diseases, advancing the work of Dr. Richard Jude Samulski at UNC’s Gene Therapy Center from the laboratory into human clinical trials to meet drug approval requirements. Operates a Sanford, North Carolina manufacturing complex using specialized methodologies and advanced techniques.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bamboo Therapeutics company profile →
Centogene
HQ: Germany
Website
- Description: Provider of methods and technology for human genetics analysis, delivering genetic diagnostic analyses of rare inherited diseases and transforming global genetic data into medical decisions to create broader awareness for patients of all ethnicities around the world.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centogene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TissueGene
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TissueGene
2.2 - Growth funds investing in similar companies to TissueGene
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TissueGene
4.2 - Public trading comparable groups for TissueGene
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →